Dallas, TX: ReportsandReports announce Sandoz International GmbH: PharmaVitae Profile Market Research Report in its Store.
Browse complete Report at: http://www.reportsandreports.com/reports/9320-sandoz-international-gmbh-pharmavitae-profile.html
This analysis examines the historical and forecast performance for Sandoz in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
• Benchmark Sandoz’s performance against key rivals in the prescription pharmaceutical sector
• Analyze the impact of Sandoz’s historical M&A activity on its geographic reach, product portfolio and manufacturing capabilities
• Consider Sandoz’s growth strategy over 200915 as it is faced by increasingly challenging conditions in its two largest markets, the US and Germany
• Table Of Contents
• ABOUT DATAMONITOR HEALTHCARE
• About the PharmaVitae team
• Chapter 1 About this profile
• PharmaVitae Explorer database
Chapter structure
Executive summary
Quarterly update
Company introduction
Company sales
Company financials
Key products
Data sourcing
Sales data
Analyst consensus
• Chapter 2 Executive summary
• Key findings
Prescription pharmaceutical sales and growth rate performance, 2003-15
Financial performance, 2002-14
Note regarding full-year 2009 financial data
Sandoz: PharmaVitae forecasts at a glance
Strategic insight
2003-09: M&A drives geographic expansion
2009-15: Roll out of biosimilar and ‘difficult to make’ generics in new markets
Sandoz as a key component of the Novartis Group
Authorized generics minimize loss of revenue to external generic competitors
Provides Novartis with a biologics arm
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
Table of Contents
Table of figures
• Chapter 3 Quarterly news update
• Latest quarterly sales
Latest prescription pharma product news
Q1 2010
Q4 2009
Q3 2009
Q2 2009
Q1 2009
Latest corporate news
Q1 2010
Q4 2009
Q3 2009
Q2 2009
Q1 2009
• Chapter 4 Company introduction
• Key findings
Background
Key corporate developments
M&A history
Novartis Generics – the pre-Sandoz years
Novartis Generics is rebranded as Sandoz
Hexal and Eon become Sandoz’s largest acquisitions to date
Ebewe acquisition brings specialty oncology injectables
Current corporate structure
• Chapter 5 Company sales
• Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003-15
Product analysis
Product analysis, 2003-09
Product analysis, 2009-15
Therapy area analysis
Geographic analysis
Molecule type analysis
Externalization analysis
• Chapter 6 Company financials
• Key findings
Note regarding full-year 2009 financial data
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08
Operating costs and profit analysis
Operating costs and profit analysis, 2002-08
Operating cost ratio and profit margin analysis, 2002-08
• Chapter 7 Key products
• Overview
Gen. Lovenox
Summary
Sales forecast
Momenta alliance offers Sandoz an unusual route into biosimilar development
Momenta is confident of a 2010 launch despite FDA approval delays
Ebewe oncology portfolio
Overview
Sales forecast
Gen. Taxotere
Overview
Sales forecast
Gen. Advair
Overview
Sales forecast
Vectura alliance brings expertise in ‘difficult to make’ respiratory products
Devices will prove key to the Advair generics market
Zarzio
Summary
Sales forecast
Gen. Losec
Overview
Sales forecast
Gen. Toprol-XL
Overview
Sales forecast
August 2007 launch of 50mg metoprolol boosted existing product line
Competition in the US will impact sales
Gen. Lotrel
Overview
Sales forecast
Sandoz launches an authorized generic of Novartis’s Lotrel
Challenge from Teva, Dr Reddy’s and Mylan forces Novartis/Sandoz to act
Authorized generics present a life cycle management strategy for Novartis
Gen. Duragesic
Overview
Sales forecast
Sandoz’s fentanyl patches are an ‘authorized’ generic of J&J’s Duragesic
Safety fears are expected to impact future sales performance
Recalls in 2008 and 2009 likely to have a lasting impact on market share
Teva enters the Duragesic market in Q3 2008
Gen. Zocor
Overview
Sales forecast
• Chapter 8 Appendix
• References
Abbreviations
Exchange rates
About Datamonitor
About Datamonitor Healthcare
Datamonitor consulting
Disclaimer
ABBREVIATIONS
Browse all : Healthcare Market Research Reports
http://www.reportsandreports.com/cat/healthcare-market-research.html
Browse all : Datamonitor Market Research Reports
http://www.reportsandreports.com/Publisher/datamonitor-market-research.html-market-research.html
Browse all Newly Published Market Research Reports
http://www.reportsandreports.com/LatestReport.aspx
Original Source : PharmaVitae Market
http://www.reportsandreports.com/reports/9320-sandoz-international-gmbh-pharmavitae-profile.html
Buy Now : Market Research Report
http://www.reportsandreports.com/
Related Reports:
Sandoz International GmbH-Detailed Product Pipeline
http://www.reportsandreports.com/reports/30683-sandoz-international-gmbh-detailed-product-pipeline.html
Sandoz International GmbH-Company Report
http://www.reportsandreports.com/reports/6201-sandoz-international-gmbh-company-report.html
Sandoz International GmbH-Deals & Alliances Report
http://www.reportsandreports.com/reports/32092-sandoz-international-gmbh-deals-alliances-report.html
Sandoz International GmbH
http://www.reportsandreports.com/reports/19888-sandoz-international-gmbh.html
Sandoz International GmbH – SWOT Analysis
http://www.reportsandreports.com/reports/2470-sandoz-international-gmbh-swot-analysis.html
About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/
